Samsung Bioepis Urges FDA for Clearer Guidance on Biosimilar Development and Regulatory Harmonization
2026-06-11
PubComNonGov2026-06-11
Carter Struck
WASHINGTON, June 11 -- Samsung Bioepis Co., Ltd., headquartered in Incheon, South Korea, submitted a public comment letter to the U.S. Food and Drug Administration (FDA) addressing the agency's draft . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and individuals; as well as 'gathered' public policy information, including news releases, reports, speeches. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
WASHINGTON, June 11 -- Samsung Bioepis Co., Ltd., headquartered in Incheon, South Korea, submitted a public comment letter to the U.S. Food and Drug Administration (FDA) addressing the agency's draft . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and individuals; as well as 'gathered' public policy information, including news releases, reports, speeches. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
Copyright © Targeted News Service, 2026